Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Moehler

Showing results (141-150 of 218) with videos related to

Pageof 22
Sort By:
Advances in Therapy|November 18, 2025
Tislelizumab + Chemotherapy in Gastric Cancer: Long-Term RATIONALE-305 Randomized Trial Follow-upMarcia Cruz-Correa, Do-Youn Oh, Ken Kato, et al.
JHEP Reports : Innovation in Hepatology|February 10, 2022
Outcomes in patients receiving palliative chemotherapy for advanced biliary tract cancerFelix Thol, Simon Johannes Gairing, Carolin Czauderna, et al.
BMJ Open|October 26, 2022
What is the gender representation in authorship in later phase systemic clinical trials in biliary tract cancer (BTC)? - a retrospective review of the published literatureMairéad G McNamara, John Bridgewater, Lipika Goyal, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|June 14, 2020
Radiochemotherapy with or without cetuximab for unresectable esophageal cancer: final results of a randomized phase 2 trial (LEOPARD-2)Dirk Rades, Tobias Bartscht, Peter Hunold, et al.
Journal of Hepatology|May 25, 2020
Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancerMairéad Geraldine McNamara, Andre Lopes, Harpreet Wasan, et al.
Critical Reviews in Oncology/Hematology|August 6, 2025
PD-1/PD-L1 inhibitors in advanced, unresectable esophageal squamous-cell carcinoma: A meta-analysis of their effects across patient subgroupsMohammed S Beshr, Rana H Shembesh, Abdelaziz H Salama, et al.
Journal of Affective Disorders|August 23, 2024
Prevalence of current suicidal thoughts and lifetime suicide attempts in individuals with cancer and other chronic diseases in Germany: Evidence for differential associations from a representative community cohortTamara Schwinn, Roman H Paul, Judith Hirschmiller, et al.
Current Medical Research and Opinion|June 18, 2025
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma: patient-reported outcomes in the RATIONALE-305 studyMarcia Cruz-Correa, Rui-Hua Xu, Markus Moehler, et al.
European Radiology|August 17, 2022
Standard diametric versus volumetric early tumor shrinkage as a predictor of survival in metastatic colorectal cancer: subgroup findings of the randomized, open-label phase III trial FIRE-3 / AIO KRK-0306Felix O Hofmann, Volker Heinemann, Melvin D'Anastasi, et al.
Hepatology (Baltimore, Md.)|June 14, 2024
Bintrafusp alfa and chemotherapy as first-line treatment in biliary tract cancer: A randomized phase 2/3 trialDo-Youn Oh, Masafumi Ikeda, Choong-Kun Lee, et al.
Pageof 22

Showing results (141-150 of 218) with videos related to

Sort By:
Pageof 22
Advances in Therapy|November 18, 2025
Tislelizumab + Chemotherapy in Gastric Cancer: Long-Term RATIONALE-305 Randomized Trial Follow-upMarcia Cruz-Correa, Do-Youn Oh, Ken Kato, et al.
JHEP Reports : Innovation in Hepatology|February 10, 2022
Outcomes in patients receiving palliative chemotherapy for advanced biliary tract cancerFelix Thol, Simon Johannes Gairing, Carolin Czauderna, et al.
BMJ Open|October 26, 2022
What is the gender representation in authorship in later phase systemic clinical trials in biliary tract cancer (BTC)? - a retrospective review of the published literatureMairéad G McNamara, John Bridgewater, Lipika Goyal, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|June 14, 2020
Radiochemotherapy with or without cetuximab for unresectable esophageal cancer: final results of a randomized phase 2 trial (LEOPARD-2)Dirk Rades, Tobias Bartscht, Peter Hunold, et al.
Journal of Hepatology|May 25, 2020
Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancerMairéad Geraldine McNamara, Andre Lopes, Harpreet Wasan, et al.
Critical Reviews in Oncology/Hematology|August 6, 2025
PD-1/PD-L1 inhibitors in advanced, unresectable esophageal squamous-cell carcinoma: A meta-analysis of their effects across patient subgroupsMohammed S Beshr, Rana H Shembesh, Abdelaziz H Salama, et al.
Journal of Affective Disorders|August 23, 2024
Prevalence of current suicidal thoughts and lifetime suicide attempts in individuals with cancer and other chronic diseases in Germany: Evidence for differential associations from a representative community cohortTamara Schwinn, Roman H Paul, Judith Hirschmiller, et al.
Current Medical Research and Opinion|June 18, 2025
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma: patient-reported outcomes in the RATIONALE-305 studyMarcia Cruz-Correa, Rui-Hua Xu, Markus Moehler, et al.
European Radiology|August 17, 2022
Standard diametric versus volumetric early tumor shrinkage as a predictor of survival in metastatic colorectal cancer: subgroup findings of the randomized, open-label phase III trial FIRE-3 / AIO KRK-0306Felix O Hofmann, Volker Heinemann, Melvin D'Anastasi, et al.
Hepatology (Baltimore, Md.)|June 14, 2024
Bintrafusp alfa and chemotherapy as first-line treatment in biliary tract cancer: A randomized phase 2/3 trialDo-Youn Oh, Masafumi Ikeda, Choong-Kun Lee, et al.
Pageof 22